Records
Browse every document routed through Assort Design.
Route Filters
Antimicrobials in plastics Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Inter
One-line summary: SANITIZED AG drives growth in plastics antimicrobials with direct sales, innovation, and end-to-end project support for Personal Care and Healthcare markets.
Citations: 3 · Risk: 1 High / 0 Medium / 0 Low
EpiCept second-quarter net loss decreases to $4.9 million Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health
One-line summary: EpiCept advances Ceplene's FDA NDA filing and European launch for AML relapse prevention, with growing clinical and commercial momentum.
Citations: 3 · Risk: 0 High / 0 Medium / 1 Low
New insights into macrophages' role in MASH and liver fibrosis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News He
One-line summary: TREM2-expressing lipid-associated macrophages are critical for resolving MASH and liver fibrosis by promoting scar tissue degradation and anti-inflammatory responses.
Citations: 3 · Risk: 1 High / 0 Medium / 0 Low
New study helps better understand the pathology of fatty liver disease MASH Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional
One-line summary: A recent study reveals that antigen-driven clonal expansion of CD8+ T cells plays a key role in MASH pathogenesis, offering insights for early diagnosis and intervention.
Citations: 5 · Risk: 1 High / 1 Medium / 0 Low
Nwd1 gene linked to liver dysfunction in metabolic disease Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health
One-line summary: Nwd1 gene deficiency disrupts ER calcium homeostasis via SERCA2 inhibition, inducing MASH-like liver dysfunction and suggesting Nwd1 as a novel therapeutic target.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Two new subtypes of MASH revealed with different risks and outcomes Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food Ne
One-line summary: A landmark study identifies two distinct MASH subtypes with differing risks and outcomes, underscoring the need for subtype-specific diagnosis and treatment.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
CePA: Novel nanomedicine for alleviating MASH via mTOR repression Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News
One-line summary: CePA, a cerium-phytic acid nanomedicine, alleviates metabolic dysfunction-associated steatohepatitis (MASH) by repressing mTOR phosphorylation, reducing hepatic lipogenesis, inflammation, and fibrosis in preclinical models.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional
One-line summary: Saturated fat increases sphingosine-1-phosphate (S1P) levels in obese individuals, driving inflammation and progression of non-alcoholic steatohepatitis (NASH), unlike unsaturated fat.
Citations: 4 · Risk: 2 High / 0 Medium / 0 Low
Study calls for new gold standard in research to treat non-alcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About F
One-line summary: The study advocates a new human-relevant gold standard using in vitro and omics techniques to better understand and treat non-alcoholic steatohepatitis (NASH), addressing limitations of current animal models.
Citations: 2 · Risk: 1 High / 1 Medium / 0 Low
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor January 9, 2026 PDF Version Agreement expands Madrigal’s pipeline and stre
One-line summary: Madrigal Pharmaceuticals expands its MASH pipeline through an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, complementing its approved therapy Rezdiffra for innovative combination MASH treatments.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low